# A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

> **NCT02772081** · PHASE3 · TERMINATED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 33 (actual)

## Conditions studied

- Respiratory Distress Syndrome (RDS)

## Interventions

- **COMBINATION_PRODUCT:** LISA combination product (Curosurf+catheter CHF6440)
- **DRUG:** Curosurf through conventional administration (endotracheal tube)

## Key facts

- **NCT ID:** NCT02772081
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-18
- **Primary completion:** 2022-08-13
- **Final completion:** 2022-08-13
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772081, "A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02772081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*